The objective of this post marketing surveillance is according to § 67 Abs. 6 AMG the documentation of data concerning efficacy and safety of Herceptin (Trastuzumab) in HER2 positive early breast cancer in current clinical practice.
The purpose of this investigation is to document the application of Herceptin as a part of routine treatment in Germany. The implementation of this post marketing surveillance does not influence the physician regarding therapy, diagnostics and frequency of medical examination during and after the treatment.